Xenia Implant (Verion 4) For Visual Rehabilitation Of Advanced Keratoconus: 9 Months Results
Published 2025 - 43rd Congress of the ESCRS
Reference: PO562 | Type: Free paper | DOI: 10.82333/xp7s-3m27
Authors: George Waring IV* 1 , Annmarie Hipsley 2 , Daniel Neal 3 , Xifeng Xiao 4 , Laurent Sabatier 5 , Edwin Price 5
1Doctor,Waring Vision Institute,Mt Pleasant,United States;Consultant,Ace Vision Group,Boston,United States, 2CEO,Ace Vision Group,Boston,United States, 3CEO,Wave Front Dynamics ,Albuquerque,United States;Consultant,Ace Vision Group,Boston,United States, 4Research,Waring Vision Institute,Albuquerque,United States;Consultant,Ace Vision Group,Boston,United States, 5Research,Ace Vision Group,Boston,United States
Purpose
To report 9 months results for a cohort of advanced keraoconus eyes implanted with an intracorneal Xenia (Verion 4) implants
on November, 2024 as a piolet study to evalute the visual, clinical, topographic and anatomical outcome.
Setting
Prospective intervential study carried out in Alex Eye Center, Alexandria, Egypt.
Methods
9 eyes of advanced keratoconus all were at the age of keratoconus activity (18 -32 Ys) and were cross linked before. Eyes had a Kmax ranged (55-79D), UCVA (0.02-0.2) and BCVA (0.1-0.5) have undergone Xenia version 4 implantation into a corneal pocket at 220 microns depth from the epithelium using Visumax® 500 femtosecond laser.
Xenia implants (version 4) are decellularised porcine lenticules of 40 microns in thickness and 6.7 mm in diameter. All eyes were implanted on November, 2024 and being followed up for the UCVA, BCVA, topographic and aberrometric change for more than 9 months at the time of the presentation.
Results
At the time of the abstract submission (4 months of follow up) showed no immunological reaction, a significat improvent in both UCVA and BCVA with a mean flattening of 9 D of the Kmax (7 -17 D) and significant reduction of the HOA especially longitudinal coma. The full 9 months follow up data will be be demonstarted at the time of presentation.
Conclusions
Prelimenary data demonstrated safety and significant improvements in visual acuity, corneal topography, and aberrometric outcomes after Xenia (Version 4) implantation. Compared to traditional surgical interventions, Xenia implant offers a reversible and relatively less invasive option for advanced keratoconus patients. This modality can avoid or defer corneal transplantation in patients with severe keratoconus as long as possible. This pilot study highlights the potential of the Xenia (Version 4) implant as a promising alternative in the evolving landscape of keratoconus management.